Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMP-002 intrathecal multiple-dose study in pediatric SYNGAP1-related disorder
NL-OMON61770Phase 2Not yet recruiting
- Sponsor
- CAMP4 Therapeutics
- Start
- Oct 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CMP-SYNGAP-01 in SYNGAP1-related disorders, sponsored by CAMP4 Therapeutics. Primary endpoints: Incidence of adverse events and Changes from baseline in clinical laboratory results. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CMP-SYNGAP-01
03
Conditions
SYNGAP1-related disorders
Beyond the preview
Go deeper on NL-OMON61770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61770.